Key result
Obesity in T2DM patients was significantly associated with the heterozygous CT genotype of the IL-4 rs2243250 polymorphism, present in 58.13% of obese patients versus 20% of normal weight patients.
Why the study?
Investigating the interplay between genetic and environmental factors is critical for effective T2DM management, prompting evaluation of the relationship between BMI, IL-4 gene polymorphism, and lifestyle factors in Northern Indian T2DM patients.
Is the IL-4 gene polymorphism (rs2243250) associated with BMI categories in patients with Type 2 diabetes mellitus?
Cross-Sectional (n=175)
Is the IL-4 gene polymorphism (rs2243250) associated with BMI categories in patients with Type 2 diabetes mellitus?
The heterozygous CT genotype of the IL-4 rs2243250 polymorphism is associated with obesity in T2DM patients, whereas the TT genotype may offer protection against elevated BMI.
May aid risk stratification in T2DM; leaves open causal role of IL-4 polymorphism.
Background: Type 2 diabetes mellitus (T2DM) is a significant global health challenge, with a particularly high prevalence among genetically predisposed populations. Environmental and lifestyle factors can activate susceptibility genes, heightening the risk of developing diabetes. Investigating the interplay between genetic and environmental factors is critical for effective T2DM management. This study examines the relationship between body mass index (BMI), the interleukin-4 (IL-4) gene polymorphism (rs2243250), and lifestyle factors among T2DM patients from Northern India. Materials and Methods: In this cross-sectional study, 175 T2DM patients were categorized into three BMI groups as follows: normal weight, overweight, and obese. Demographic data were collected via surveys, and genotyping was performed using the tetra-primer amplification refractory mutation system. Statistical analyses included chi-square tests and one-way analysis of variance, with 95% confidence intervals (CIs) and odds ratios (OR) calculated to assess the risk associated with the IL-4 polymorphism. A P < 0.05 was considered statistically significant. Results: The heterozygous CT genotype of the IL-4 rs2243250 polymorphism was significantly associated with obesity, observed in 58.13% of obese patients, compared to 40.68% in the overweight group and 20% in the normal BMI group. Most patients (82) were treated with a combination therapy of metformin, pioglitazone, and glimepiride, effectively improving triglycerides, HbA1c, high-density lipoprotein (HDL), and blood glucose levels across all BMI categories. Conclusion: The TT genotype of the IL-4 rs2243250 polymorphism may protect against elevated BMI in T2DM patients. Further studies are needed to unravel the complex interactions between genetic polymorphisms, BMI, and lifestyle factors to enhance diabetes management strategies.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2025) conducted a cross-sectional in Type 2 diabetes mellitus (n=175). Obesity vs. Normal weight was evaluated on Presence of heterozygous CT genotype of the IL-4 rs2243250 polymorphism. Obesity in T2DM patients was significantly associated with the heterozygous CT genotype of the IL-4 rs2243250 polymorphism, present in 58.13% of obese patients versus 20% of normal weight patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: